 Adamas Pharmaceuticals, Inc. ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Application sNDA for GOCOVRI as a treatment for OFF episodes in Parkinsons disease PD patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration FDA. GOCOVRI amantadine extended release capsules is approved to treat dyskinesia in PD patients treated with levodopa-based therapy, with or without other dopaminergic medications. 